Company intelligence / Profile preview

Advanced Prenatal Therapeutics

Laguna Hills, California, United Statesadvancedprenatal.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Advanced Prenatal Therapeutics has developed a novel targeted apheresis medical device designed to selectively remove harmful circulating proteins such as sFlt–1 implicated in preeclampsia from the mother’s blood. This approach aims to alleviate symptoms of preeclampsia and prolong pregnancy duration safely, potentially reducing premature births and associated lifelong disabilities. The technology has received FDA Breakthrough Device Designation and won the California Investment Forum Innovation Award in May 2024.

Therapeutic areas: ImmunologyWomen's Health
Modalities: DeviceTargeted apheresis column
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

TAC-PE

Pre-clinical

Indications: Preeclampsia

Beyond the preview

Go deeper on Advanced Prenatal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Prenatal Therapeutics.

Explore the full profile